MESO — MESOBLAST LTD
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1345099 ·
Last close
$14.17
Market Cap
$1.84B
52W High
$19.36
52W Low
$13.05
ADV30
273,157
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | — | — | — | — | 782,307,000 | 129,573,000 | 207,623,000 |
| Sep 2025 | — | — | — | — | — | — | — |
| Jun 2025 | — | — | — | — | 784,683,000 | 161,158,000 | 187,241,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,051,065,000
Inventory
$21,664,000
Receivables
$43,300,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$65,384,000
EBITDA
$-64,339,000
Free Cash Flow
$-69,438,336
Enterprise Value
$1,830,994,688
Total Cash
$129,975,000
Total Debt
$135,144,000
Shares Out
129,696,087
Trailing EPS
$-0.67
Book Value
$4.46
ROE
-18.2%
ROA
-6.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 17,198,000 | -62,443,000 | -102,142,000 | 784,683,000 | 187,241,000 | — | -49,954,000 |
| Jun 2024 | 5,902,000 | -57,972,000 | -87,956,000 | 669,153,000 | 188,798,000 | — | -48,458,000 |
| Jun 2023 | 7,501,000 | -69,289,000 | -81,889,000 | 669,415,000 | 167,577,000 | — | -63,269,000 |
| Jun 2022 | 10,211,000 | -81,107,000 | -91,347,000 | 662,142,000 | 165,098,000 | — | -65,782,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $1.82B | $4.07 | — |
| ADMA | ADMA BIOLOGICS, INC. | $1.96B | $8.46 | — |
| IMCR | Immunocore Holdings plc | $1.72B | $33.81 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.68B | $5.86 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.57B | $3.00 | — |
News headlines (Yahoo Finance, 1h cache)
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
2026-07-30 00:57 · Yahoo
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?
2026-07-17 16:00 · Yahoo
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
2026-07-14 00:35 · Yahoo
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Amid Renewed US-Iran Tensions Ahead of Q2 Earnings Season
2026-07-10 13:07 · Yahoo
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
2026-07-10 00:30 · Yahoo
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
2026-07-01 00:38 · Yahoo
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
2026-06-25 00:59 · Yahoo
Kina Securities And 2 Other Stocks That May Be Trading Below Their Estimated Value On The ASX
2026-06-11 19:35 · Yahoo
ASX Growth Companies With High Insider Ownership
2026-05-31 19:38 · Yahoo
ASX Penny Stocks With Market Caps Under A$3B To Consider
2026-05-28 03:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.